


IN THE CLAIMS


The following claim set replaces all prior versions, and listings, of claims in the application:

1-7 canceled.

8. (Currently Amended) A 2-aminoteraline of the formula (I)



or a pharmacologically acceptable salt of the formula (II)



wherein:

R and R₁ are independently halogen, hydroxy, or C₁-C₄ alkoxy optionally substituted in position ω with a group selected from OH, NH₂ or NR₃R₄, wherein R₃ and R₄ are independently H, C₁-C₄ alkyl, unsubstituted or substituted in position ω with groups OH, NH₂, C₁-C₄ alkanoyl, C₁-C₄ alkyl, carbamoyl, carbamoyloxy, amino, or amino-substituted NR₃R₄, where R₃ and R₄ have the above meanings,

R₂ is hydrogen, ~~halogen~~, hydroxy or methoxy,
with the proviso that the 2-aminotetraline excludes (a) R=R₁=CH₃O or OH, R₂=H, (b) R=F, R₁=CH₃O or OH, R₂=H, (c) R₁=R₂=-OCH₃ and R₂=H, (d) R=R₁=R₂=CH₃O, (e) R=R₁=Cl and R₂=H, (f) R=R₁-F and R₂=H, (g) R=OH and R₁=R₂=halogen, (h) R=R₁=OH and R₂=Cl or F or (i) R=R₁=OCH₃ and R₂=Cl or F,

and X⁻ is the monovalent anion of a pharmacologically acceptable acid.

9. (Previously Added) A compound according to claim 8, wherein the monovalent anion of a pharmacologically acceptable acid is selected from chloride, bromide, orotate, acid aspartate, acid citrate, acid phosphate, fumarate and acid fumarate, lactate, maleate and acid maleate, acid oxalate, acid sulphate, glucose phosphate, tartrate and acid tartrate.

10. (Previously Added) A compound selected from the group consisting of:

S(-)-2-amino-6-fluoro-7-hydroxytetraline hydrochloride;

R(+)-2-amino-6-fluoro-7-hydroxytetraline hydrochloride;

(R,S)-2-amino-5,6-difluoro-7-methoxytetraline hydrochloride;

(R,S)-2-amino-6-fluoro-7-methyltetraline hydrochloride;

(R,S)-2-amino-7-fluoro-6-hydroxytetraline hydrochloride;

42
~~(R,S)-7-acetyl-2-amino-6-methyltetraline hydrochloride; and~~

~~(R,S)-2-amino-7-fluoro-6-methoxytetraline hydrochloride.~~

11. (Previously Added) An orally or parenterally administrable pharmaceutical composition containing a compound of claim 8 and a pharmaceutically acceptable carrier and/or diluent.

3
~~12-20. canceled.~~